13.18

0.73% 0.095

After Hours: 13.25 0.07 +0.53%

Oculis Holding Ag (OCS)

Overview News Price History Discussions Forecast

Oculis Holding Ag stock is traded at $13.18, with a volume of 150.35K. It is up +0.73% in the last 24 hours and up +18.42% over the past month. Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Previous Close:

$13.09

Open:

$13.1

24h Volume:

150.35K

Relative Volume:

0.24

Market Cap:

$731.86M

Revenue:

Net Income/Loss:

$-117.99M

P/E Ratio:

-6.1597

EPS:

-2.1397

Net Cash Flow:

$-79.92M

1W Performance:

+0.30%

1M Performance:

+18.42%

6M Performance:

-55.52%

1Y Performance:

-26.16%

1-Day Range:

$12.87

$13.25

1-Week Range:

$12.87

$13.70

52-Week Range:

$10.52

$34.48

Oculis Holding Ag Stock (OCS) Company Profile

Name

Oculis Holding Ag

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-20

Latest SEC Filings

OCS's Discussions on Twitter

Compare OCS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCS Oculis Holding Ag	13.18	729.64M	0	-117.99M	-79.92M	-2.1397
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Oculis Holding Ag Stock (OCS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-25	Initiated	JP Morgan	Overweight
Aug-27-25	Initiated	Needham	Buy
Dec-05-23	Initiated	Chardan Capital Markets	Buy
Oct-05-23	Initiated	Stifel	Buy
Jun-14-23	Initiated	BofA Securities	Buy
Jun-12-23	Initiated	H.C. Wainwright	Buy
Jun-08-23	Initiated	Robert W. Baird	Outperform
May-10-23	Initiated	Pareto	Buy
Apr-28-23	Initiated	Wedbush	Outperform

View All

Oculis Holding Ag Stock (OCS) Latest News

Aug 20, 2026

Enterprise value to revenue forward of Oculis Holding AG – FWB:CR5 - TradingView

Aug 20, 2026

Aug 18, 2026

Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionAnchored VWAP - vinanet.vn

Aug 18, 2026

Oculis (OCSAW) Session-Level Review: Ends Up by 6.00% at $5.04 in the Latest Session; Current Setup: the Near-Term Reference Band Stretches From $4.79 to $5.29 in the Current UpdateAggressive Growth Picks - vinanet.vn

Aug 18, 2026

Aug 16, 2026

Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportDouble Top - vinanet.vn

Aug 16, 2026

Aug 14, 2026

Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Nigeria

Aug 14, 2026

The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily

Aug 14, 2026

Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan

Aug 14, 2026

Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co. - MarketBeat

Aug 14, 2026

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research

Aug 14, 2026

Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com

Aug 14, 2026

Aug 12, 2026

Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation Range NarrowsVolatility Breakout Picks - Vinanet

Aug 12, 2026

Oculis buys out privosegtor’s global rights from Accure - Glance by Eyes On Eyecare

Aug 12, 2026

HC Wainwright Has Negative Estimate for Oculis Q3 Earnings - MarketBeat

Aug 12, 2026

Aug 11, 2026

Oculis rebuilds pipeline with Privosegtor buy from Accure - AllSci

Aug 11, 2026